Epizyme Inc (NASDAQ:EPZM)‘s stock had its “outperform” rating reiterated by stock analysts at Cann in a research report issued on Wednesday. They currently have a $26.00 price objective on the biopharmaceutical company’s stock. Cann’s price target suggests a potential upside of 79.31% from the stock’s current price.
A number of other research analysts have also recently commented on EPZM. Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Wednesday, December 14th. Royal Bank of Canada restated an “outperform” rating and issued a $19.00 target price (down previously from $26.00) on shares of Epizyme in a research note on Saturday, March 11th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $23.88.
Shares of Epizyme (NASDAQ:EPZM) traded up 5.17% on Wednesday, reaching $15.25. The company’s stock had a trading volume of 177,083 shares. The stock has a 50-day moving average of $15.55 and a 200 day moving average of $11.98. The company’s market cap is $888.28 million. Epizyme has a 52-week low of $7.02 and a 52-week high of $17.80.
Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Thursday, March 9th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.05. Epizyme had a negative return on equity of 41.56% and a negative net margin of 1,205.01%. On average, equities research analysts forecast that Epizyme will post ($2.55) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece was published by sleekmoney and is owned by of sleekmoney. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at http://sleekmoney.com/cann-begins-coverage-on-epizyme-inc-epzm/1737550.html.
In other news, insider Robert A. Copeland sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 4th. The stock was sold at an average price of $16.36, for a total value of $81,800.00. Following the completion of the transaction, the insider now owns 33,538 shares in the company, valued at approximately $548,681.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Andrew E. Singer sold 2,013 shares of the firm’s stock in a transaction that occurred on Friday, March 31st. The shares were sold at an average price of $17.09, for a total value of $34,402.17. Following the completion of the transaction, the chief financial officer now owns 36,175 shares of the company’s stock, valued at approximately $618,230.75. The disclosure for this sale can be found here. Company insiders own 25.40% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Palo Alto Investors LLC boosted its position in shares of Epizyme by 7.9% in the fourth quarter. Palo Alto Investors LLC now owns 3,035,796 shares of the biopharmaceutical company’s stock worth $36,733,000 after buying an additional 221,256 shares during the last quarter. Deerfield Management Co. boosted its position in shares of Epizyme by 449.9% in the fourth quarter. Deerfield Management Co. now owns 1,601,049 shares of the biopharmaceutical company’s stock worth $19,373,000 after buying an additional 1,309,870 shares during the last quarter. State Street Corp boosted its position in shares of Epizyme by 49.4% in the fourth quarter. State Street Corp now owns 1,088,635 shares of the biopharmaceutical company’s stock worth $13,173,000 after buying an additional 359,859 shares during the last quarter. Rock Springs Capital Management LP boosted its position in shares of Epizyme by 7.5% in the third quarter. Rock Springs Capital Management LP now owns 642,500 shares of the biopharmaceutical company’s stock worth $6,322,000 after buying an additional 45,000 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Epizyme during the fourth quarter worth about $5,961,000. Institutional investors and hedge funds own 79.98% of the company’s stock.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/cann-begins-coverage-on-epizyme-inc-epzm/1737550.html
Receive News & Ratings for Epizyme Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc and related companies with MarketBeat.com's FREE daily email newsletter.